24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients
HIV MEDICINE（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要